08 Jul Health regulators warn against the use or dispensing of recalled Semaglutide and Tirzepatide
Pretoria, 08 July 2026 – The South African Pharmacy Council (SAPC), Health Professions Council of South Africa (HPCSA) and the South African Health Products Regulatory Authority (SAHPRA) hereby warn the public, pharmacies and dispensing medical practitioners against any continued use, prescription and/or dispensing of iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide recalled by SAHPRA in June 2026.
The continued use, prescription and dispensing of these products pose a severe risk to patients’ safety and/or users. Any healthcare professional found to have dispensed, prescribed or kept stock of the recalled products will face disciplinary action in accordance with applicable legislation, including the Medicines and Related Substances Act, 101 of 1965.
In a Class I, Type A Recall, SAHPRA determined that iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide pose serious safety risk to patients. Thus, any professional found to be prescribing or dispensing them to patients or users will knowingly be endangering the health of the public.
The recall notice, which contains a list of the recalled products, may be accessed at: https://www.sahpra.org.za/document/idexis-semaglutide-idexis-tirzepatide-idexissemaglutide-tirzepatide/